What dose of bempedoic acid can be added to a regimen of 40 mg pravastatin (PRV) and 10 mg ezetimibe (EZE) for an adult with established cardiovascular disease and elevated low-density lipoprotein cholesterol (LDL-C), and is it available over the counter (OTC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bempedoic Acid Dosing with Pravastatin and Ezetimibe

Add bempedoic acid 180 mg once daily to your current regimen, but you cannot obtain it over the counter—it requires a prescription. 1, 2

Standard Dosing

  • The dose of bempedoic acid is fixed at 180 mg orally once daily, regardless of your current lipid-lowering therapy or LDL-C levels. 1, 2
  • This medication can be taken with or without food and should be swallowed whole. 1, 2
  • There is no dose adjustment needed when adding bempedoic acid to your pravastatin 40 mg and ezetimibe 10 mg regimen. 1, 2

Critical Drug Interaction with Your Current Pravastatin

Your pravastatin dose of 40 mg is at the maximum allowed when combining with bempedoic acid. 1, 2 The American College of Cardiology specifically warns against using pravastatin doses exceeding 40 mg daily when combined with bempedoic acid due to increased drug exposure risk. 1, 2 Since you are already at this threshold, do not increase your pravastatin dose further.

Prescription Requirement

  • Bempedoic acid is not available over the counter—it is a prescription medication that requires prior authorization in most cases. 1
  • The medication was FDA-approved in 2020 for adults with established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-C lowering beyond maximally tolerated statin therapy. 1, 3

Expected LDL-C Reduction

  • When added to your current statin and ezetimibe combination, bempedoic acid provides an additional 17-18% placebo-corrected reduction in LDL-C. 1
  • The triple combination of statin + ezetimibe + bempedoic acid can achieve approximately 38% total LDL-C reduction compared to baseline. 1, 4

Required Safety Monitoring

Before starting bempedoic acid, your physician should check your baseline serum uric acid level. 1, 2 The American College of Cardiology recommends:

  • Uric acid monitoring: Expect a mean increase of 0.8 mg/dL in serum uric acid. 1, 2, 5 Contact your physician if you develop symptoms of gout (joint pain, swelling, particularly in the big toe). 1
  • Tendon monitoring: Immediately report any tendon pain, swelling, or inflammation, as bempedoic acid carries a risk of tendinitis and tendon rupture. 1, 2 Discontinue the medication immediately if tendon rupture occurs. 1
  • Liver enzyme monitoring: Periodic monitoring of liver function tests is recommended as clinically indicated. 1, 2

Advantages of This Combination

  • No increased muscle-related side effects: Unlike statins, bempedoic acid is a prodrug that is only activated in the liver (not skeletal muscle), so it does not increase the risk of myalgia or myopathy. 4, 5
  • No diabetes risk: Bempedoic acid does not increase the risk of new-onset diabetes and may even modestly improve glycemic control. 6, 4
  • Cardiovascular outcomes benefit: Recent trials show bempedoic acid reduces major adverse cardiovascular events by 13% overall, and by 30% in high-risk patients with established cardiovascular disease. 6

Common Pitfall to Avoid

Do not adjust the bempedoic acid dose based on your LDL-C response—the dose remains 180 mg daily regardless of lipid levels achieved. 2 The American College of Cardiology emphasizes this is a fixed-dose medication, not one that requires titration. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bempedoic Acid Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Bempedoic Acid: for Whom and When.

Current atherosclerosis reports, 2022

Research

Role of Bempedoic Acid in Clinical Practice.

Cardiovascular drugs and therapy, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.